India now making moves into pharma innovation
In what must be seen as a significant change in focus, India is now seeing a surge of innovative research in the pharmaceutical and biosimilars sectors, moving away from its traditional role in generics and active pharmaceutical ingredients, reports The Pharma Letter’s India correspondent.
In a major first, a novel patented thrombolytic therapeutic protein drug has been given the go ahead by the Drugs Controller General of India to conduct Phase II clinical trials.
Licensed from India’s Council of Scientific and Industrial Research Institute of Microbial Technology, Chandigarh (The Pharma Letter March 2, 2009), trials would be conducted to test the efficacy of the clot specific streptokinase (CSSK) in heart attack patients. Nostrum Pharmaceuticals of the USA is the parent company of Symmetrix Biotech, which has been carrying out the clinical development of CSSK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze